A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Latest Information Update: 07 Sep 2023
At a glance
- Drugs Nivolumab (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 14 Aug 2023 Status changed from active, no longer recruiting to completed.
- 28 Sep 2022 Results assessing clinicopathological characteristics and tumour microenvironment to identify potential biomarkers using tumour samples from patients enrolled in this trial published in the European Journal of Cancer
- 15 Aug 2022 Planned End Date changed from 30 Jul 2022 to 30 Jul 2023.